The target backsheath field acceleration mechanism is one of the main mechanisms of laser-driven proton acceleration(LDPA)and strongly depends on the comprehensive performance of the ultrashort ultra-intense lasers us...The target backsheath field acceleration mechanism is one of the main mechanisms of laser-driven proton acceleration(LDPA)and strongly depends on the comprehensive performance of the ultrashort ultra-intense lasers used as the driving sources.The successful use of the SG-II Peta-watt(SG-II PW)laser facility for LDPA and its applications in radiographic diagnoses have been manifested by the good performance of the SG-II PW facility.Recently,the SG-II PW laser facility has undergone extensive maintenance and a comprehensive technical upgrade in terms of the seed source,laser contrast and terminal focus.LDPA experiments were performed using the maintained SG-II PW laser beam,and the highest cutoff energy of the proton beam was obviously increased.Accordingly,a double-film target structure was used,and the maximum cutoff energy of the proton beam was up to 70 MeV.These results demonstrate that the comprehensive performance of the SG-II PW laser facility was improved significantly.展开更多
The continued development of clustered regularly interspaced short palindromic repeats(CRISPR)technology has the potential to greatly impact clinical medicine,particularly for disease diagnosis and treatment.Despite h...The continued development of clustered regularly interspaced short palindromic repeats(CRISPR)technology has the potential to greatly impact clinical medicine,particularly for disease diagnosis and treatment.Despite high demand for the in vivo delivery of CRISPR-based therapies,significant challenges persist.These include rapid degradation by enzymes,inefficient disease site targeting,and the risk of undesired off-target outcomes.Nanoparticulate platforms,with their tailorable properties,have been engineered to efficiently package CRISPR payloads in various formats,including as plasmid DNA,mRNA,and ribonucleoprotein complexes,for in vivo delivery.Among them,recombinant adeno-associated viruses,virus-like particles,and lipid nanoparticles have displayed exceptional promise.This review will discuss the development of these and other nanocarriers for in vivo CRISPR-based genome editing.展开更多
基金National Natural Science Foundation of China(Grant No.12075227)the National Natural Science Foundation of China-NSAF(Grant No.U2130121)+1 种基金the National Key Research and Development Program of China(Grant No.2016YFA0401102)the Science Challenge Project(Grant No.TZ2018005).
文摘The target backsheath field acceleration mechanism is one of the main mechanisms of laser-driven proton acceleration(LDPA)and strongly depends on the comprehensive performance of the ultrashort ultra-intense lasers used as the driving sources.The successful use of the SG-II Peta-watt(SG-II PW)laser facility for LDPA and its applications in radiographic diagnoses have been manifested by the good performance of the SG-II PW facility.Recently,the SG-II PW laser facility has undergone extensive maintenance and a comprehensive technical upgrade in terms of the seed source,laser contrast and terminal focus.LDPA experiments were performed using the maintained SG-II PW laser beam,and the highest cutoff energy of the proton beam was obviously increased.Accordingly,a double-film target structure was used,and the maximum cutoff energy of the proton beam was up to 70 MeV.These results demonstrate that the comprehensive performance of the SG-II PW laser facility was improved significantly.
基金supported by the Defense Threat Reduction Agency Joint Science and Technology Office for Chemical and Biological Defense(No.HDTRA1-21-1-0010)the National Institutes of Health(Nos.R21AI159492,and R21AI175904).
文摘The continued development of clustered regularly interspaced short palindromic repeats(CRISPR)technology has the potential to greatly impact clinical medicine,particularly for disease diagnosis and treatment.Despite high demand for the in vivo delivery of CRISPR-based therapies,significant challenges persist.These include rapid degradation by enzymes,inefficient disease site targeting,and the risk of undesired off-target outcomes.Nanoparticulate platforms,with their tailorable properties,have been engineered to efficiently package CRISPR payloads in various formats,including as plasmid DNA,mRNA,and ribonucleoprotein complexes,for in vivo delivery.Among them,recombinant adeno-associated viruses,virus-like particles,and lipid nanoparticles have displayed exceptional promise.This review will discuss the development of these and other nanocarriers for in vivo CRISPR-based genome editing.
